Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.
Mahalingam
Devalingam
D
Institute of Drug Development, Division of Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, Texas, USA.
Mita
Alain
A
Mita
Monica M
MM
Nawrocki
Steffan T
ST
Giles
Francis J
FJ
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001499:Bayes Theorem; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D016503:Drug Delivery Systems / Q000639:trends*; D006655:Histone Deacetylases / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010818:Practice Patterns, Physicians' / Q000639:trends; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D018714:Radiotherapy, Adjuvant; D017526:Receptor, IGF Type 1 / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D011505:Protein-Tyrosine Kinases; D017526:Receptor, IGF Type 1; D006655:Histone Deacetylases